Retinal pigment epithelial characteristics in eyes with neovascular age-related macular degeneration : Long-term retinal changes under anti-vascular endothelial growth factor treatment.
Angiogenesis Inhibitors
Child
Child, Preschool
Fluorescein Angiography
Follow-Up Studies
Humans
Intravitreal Injections
Ranibizumab
Retina
Retinal Pigment Epithelium
Retinal Pigments
Retrospective Studies
Tomography, Optical Coherence
Vascular Endothelial Growth Factor A
Visual Acuity
Wet Macular Degeneration
/ diagnosis
Bevacizumab
Hyperreflective intraretinal foci
Ranibizumab
Retina
Spectral domain optical coherence tomography
Journal
Wiener klinische Wochenschrift
ISSN: 1613-7671
Titre abrégé: Wien Klin Wochenschr
Pays: Austria
ID NLM: 21620870R
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
09
09
2019
accepted:
08
07
2020
pubmed:
8
8
2020
medline:
13
2
2021
entrez:
8
8
2020
Statut:
ppublish
Résumé
The aim of this study was to assess retinal pigment epithelial (RPE) and retinal structural changes in eyes with neovascular age-related macular degeneration (AMD) treated with anti-vascular endothelial growth factor (anti-VEGF) during long-term follow-up and to evaluate morphological markers potentially influencing prognosis. A total of 18 eyes of 18 patients with neovascular AMD were examined subsequent to completion of the Avastin Versus Lucentis in Age Related Macular Degeneration (MANTA) study following a mean period of 84 months (range 69-93 months). After receiving a loading dose of 3 intravitreal anti-VEGF injections subsequent to baseline of the MANTA study, patients were treated as needed (pro re nata, PRN). Functional and morphological changes were assessed, the latter using spectral domain optical coherence tomography (SD-OCT). Retinal/RPE atrophy generally increased significantly during follow-up compared to baseline (fibrosis 28% vs. 89%, p = 0.0001, geographic atrophy, GA 0% vs. 67%, p = 0.0002, RPE porosity 61% vs. 100%, p = 0.009) whereas regenerative alterations tendentially increased until 3 months and then subsequently declined until the last visit (RPE thickening 28% vs. 11%, p = 0.22 and intraretinal hyperreflective foci 89% vs. 78%, p = 0.39). Atrophic alterations of the retina and RPE are progressive and may partly be induced by anti-VEGF. Morphological findings may aid in the identification of prognostic markers in the progression of neovascular AMD. This could lead to a more targeted education of affected patients.
Identifiants
pubmed: 32761460
doi: 10.1007/s00508-020-01718-6
pii: 10.1007/s00508-020-01718-6
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Retinal Pigments
0
Vascular Endothelial Growth Factor A
0
Ranibizumab
ZL1R02VT79
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
123-130Références
Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The beaver dam eye study. Ophthalmology. 1992;99(6):933–43.
doi: 10.1016/S0161-6420(92)31871-8
Friedman DS, O’Colmain BJ, Munoz B. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122(4):564–72.
doi: 10.1001/archopht.1941.00870100042005
Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012;119:1399–411.
doi: 10.1016/j.ophtha.2012.04.015
Tufail A, Patel PJ, Egan C, Hykin P, et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicenter randomised double masked study. BMJ. 2010; https://doi.org/10.1136/bmj.c2459 .
doi: 10.1136/bmj.c2459
pubmed: 20538634
Busbee BG, Ho AC, Brown DM, HARBOR Study Group.. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013;120(5):1046–56.
doi: 10.1016/j.ophtha.2012.10.014
Chang TS, Bressler NM, Fine JT, MARINA Study Group, et al. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol. 2007;125(11):1460–9.
doi: 10.1001/archopht.125.11.1460
Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007;143:566–83.
doi: 10.1016/j.ajo.2007.01.028
CATT Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897–908.
doi: 10.1056/NEJMoa1102673
IVAN Study Investigators, Chakravarthy U, Harding SP, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012;119:1399–411.
doi: 10.1016/j.ophtha.2012.04.015
Regatieri CV, Branchini L, Fujimoto JG, et al. Choroidal imaging using spectral-domain optical coherence tomography. Retina. 2012;32:865–76.
doi: 10.1097/IAE.0b013e318251a3a8
Regatieri CV, Branchini L, Duker JS. The role of spectral-domain OCT in the diagnosis and management of neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2011;42:S56–66.
doi: 10.3928/15428877-20110627-05
Kumar N, Mrejen S, Fung AT, et al. Retinal pigment epithelial cell loss assessed by fundus autofluorescence imaging in neovascular age-related macular degeneration. Ophthalmology. 2013;120:334–41.
doi: 10.1016/j.ophtha.2012.07.076
Grunwald JE, Daniel E, Huang J. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2014;121:150–61.
doi: 10.1016/j.ophtha.2013.08.015
Schütze C, Wedl M, Baumann B, et al. Progression of retinal pigment epithelial atrophy in antiangiogenic therapy of neovascular age-related macular degeneration. Am J Ophthalmol. 2015;159:1100–14.
doi: 10.1016/j.ajo.2015.02.020
Grunwald JE, Pistilli M, Ying GS, et al. Comparison of age-related macular degeneration treatments trials research group. Incidence and growth of geographic atrophy during 5 years of comparison of Age-related macular degeneration treatments trials. Ophthalmology. 2017;124:97–104.
doi: 10.1016/j.ophtha.2016.09.012
Krebs I, Schmetterer L, Boltz A, MANTA Research Group, et al. A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol. 2013;97:266–71.
doi: 10.1136/bjophthalmol-2012-302391
Schmitz-Valckenberg S, Fleckenstein M, Göbel AP, et al. Optical coherence tomography and autofluorescence findings in areas with geographic atrophy due to age-related macular degeneration. Invest Ophthalmol Vis Sci. 2011;52:1–6.
doi: 10.1167/iovs.10-5619
Bird AC, Phillips RL, Hageman GS. Geographic atrophy: a histopathological assessment. JAMA Ophthalmol. 2014;132:338–45.
doi: 10.1001/jamaophthalmol.2013.5799
Jaffe GJ, Martin DF, Toth CA, et al. Comparison of age-related macular degeneration treatments trials research group. Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2013;120:1860–70.
doi: 10.1016/j.ophtha.2013.01.073
Thavikulwat AT, Jacobs-El N, Kim JS, Agrón E, et al. Evolution of geographic atrophy in participants treated with ranibizumab for neovascular age-related macular degeneration. Ophthalmol Retina. 2017;1:34–41.
doi: 10.1016/j.oret.2016.09.005
Tsuboi S, Pederson JE, Toris CB. Functional recovery of retinal pigment epithelial damage in experimental retinal detachment. Invest Ophthalmol Vis Sci. 1987;28(11):1788–94.
pubmed: 3667150
Ho J, Witkin AJ, Liu J, et al. Documentation of intraretinal retinal pigment epithelium migration via high-speed ultrahigh-resolution optical coherence tomography. Ophthalmology. 2011;118:687–93.
doi: 10.1016/j.ophtha.2010.08.010
Lee JY, Folgar FA, Maguire MG. Outer retinal tubulation in the comparison of age-related macular degeneration treatments trials (CATT). Ophthalmology. 2014;121:2423–31.
doi: 10.1016/j.ophtha.2014.06.013
Zweifel SA, Engelbert M, Laud K, et al. Outer retinal tubulation a novel optical coherence tomography finding. Arch Ophthalmol. 2009;127:1596–602.
doi: 10.1001/archophthalmol.2009.326
Curcio CA, Zanzottera EC, Ach T, et al. Activated retinal pigment epithelium, an optical coherence tomography biomarker for progression in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2017;58(6):211–26.